{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Lu YP"],"funding":["Zhao Yi-Cheng Medical Science Foundation"],"pagination":["683-696"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8443994"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["39(4)"],"pubmed_abstract":["<h4>Purpose</h4>We conducted a systematic review and meta-analysis to quantify the association between phosphodiesterase type 5 inhibitors (PDE5Is) use and skin cancers and we also examined whether down-expression of the PDE5A gene was related to worse prognosis for malignant melanoma (MM) patients.<h4>Materials and methods</h4>The PubMed, Cochrane Library, Web of Science, EMBASE, and ClinicalTrails.gov databases were searched. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to evaluate the association between PDE5Is use and risk of skin cancers. Cumulative meta-analysis and trial sequential analysis (TSA) were also conducted. Survival outcomes were analyzed online.<h4>Results</h4>After pooling all 8 eligible studies comprising 7,479,852 subjects, we found that PDE5Is "],"journal":["The world journal of men's health"],"pubmed_title":["Phosphodiesterase Type 5 Inhibitors and Risk of Skin Cancers in Men: A Meta-Analysis and Trial Sequential Analysis Involving 7,479,852 Subjects."],"pmcid":["PMC8443994"],"funding_grant_id":["ZYYFY2018031"],"pubmed_authors":["Liu X","Liu K","Yang Y","Liang Z","Lu YP","Wang X","Kang J","Fan S","Zhou K","Song Y"],"additional_accession":[]},"is_claimable":false,"name":"Phosphodiesterase Type 5 Inhibitors and Risk of Skin Cancers in Men: A Meta-Analysis and Trial Sequential Analysis Involving 7,479,852 Subjects.","description":"<h4>Purpose</h4>We conducted a systematic review and meta-analysis to quantify the association between phosphodiesterase type 5 inhibitors (PDE5Is) use and skin cancers and we also examined whether down-expression of the PDE5A gene was related to worse prognosis for malignant melanoma (MM) patients.<h4>Materials and methods</h4>The PubMed, Cochrane Library, Web of Science, EMBASE, and ClinicalTrails.gov databases were searched. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to evaluate the association between PDE5Is use and risk of skin cancers. Cumulative meta-analysis and trial sequential analysis (TSA) were also conducted. Survival outcomes were analyzed online.<h4>Results</h4>After pooling all 8 eligible studies comprising 7,479,852 subjects, we found that PDE5Is ","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Oct","modification":"2025-04-04T19:44:41.261Z","creation":"2022-02-11T11:31:10.168Z"},"accession":"S-EPMC8443994","cross_references":{"pubmed":["33151043"],"doi":["10.5534/wjmh.200082"]}}